Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Prices $2.7M Securities Offering

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has priced a public offering of 1.9 million securities units at $1.40 each for gross proceeds of roughly $2.7 million.

The units consist of one ordinary share and a warrant to purchase half an ordinary share. The warrants to purchase an aggregate of 974,987 ordinary shares have an exercise price of $1.50 per ordinary share. The warrants will become exercisable immediately upon issuance and expire in five years.

Rosetta said it would use the proceeds of the offering, which is expected to close on or about August 9, for its operations and for other general corporate purposes, which include repayment or refinancing of indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development, and product development.

During morning trading on the Nasdaq, shares of Rosetta were down 10 percent at $1.46.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.